Confidence in Concept 2012 - Queen's University Belfast

Lead Research Organisation: Queen's University of Belfast

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.

Technical Summary

The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding.  It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.

Publications

10 25 50

publication icon
Schmid D (2014) Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine. in Molecular therapy : the journal of the American Society of Gene Therapy

 
Description Development of EGFR-targeted camptothecin-loaded nanoparticles for targeting Kras wild-type colorectal cancer
Amount £110,000 (GBP)
Organisation Medical Research Council (MRC) 
Sector Public
Country United Kingdom
Start  
 
Description Development of a Novel Bioinspired Fibre Reinforced Hydrogel that Recapitulates the Developmental Processes to Regenerate the Bone-Ligament Interface
Amount £885,000 (GBP)
Organisation National Science Foundation (NSF) 
Sector Public
Country United States
Start  
 
Description Grant for R&D
Amount £306,000 (GBP)
Organisation Invest Northern Ireland 
Sector Public
Country United Kingdom
Start  
 
Description Invest NI - Almac Collaboration
Amount £3,106,000 (GBP)
Organisation NIS Ltd 
Sector Private
Country United Kingdom
Start  
 
Description Proof of Concept - Development of thermo-sensitive growth factor delivering hydrogels incorporating calcium phosphate releasing nanoparticles for the targeted promotion of endochondral bone formation to facilitate strategic regeneration of bone-tissue int
Amount £106,000 (GBP)
Organisation Invest Northern Ireland 
Sector Public
Country United Kingdom
Start  
 
Description Protease-Tags: Development and Clinical Validation as Point-of-Care Diagnostics for Respiratory Disease
Amount £183,000 (GBP)
Organisation Cystic Fibrosis Foundation 
Department Cystic Fibrosis Foundation Therapeutics
Sector Charity/Non Profit
Country United States
Start  
 
Description Sponsored research
Amount £122,000 (GBP)
Organisation Proaxsis Ltd 
Sector Private
Country United Kingdom
Start  
 
Description Targeting treatment resistant cancer stem cells utilizing FKBPL-based therapeutic peptides; towards effective drug combination strategies for clinical trial.
Amount £405,000 (GBP)
Organisation Invest Northern Ireland 
Sector Public
Country United Kingdom
Start  
End 06/2015
 
Description The utility of MN as a dosage form capable of reducing methotrexate side effects in children
Amount £200,000 (GBP)
Organisation Versus Arthritis 
Sector Charity/Non Profit
Country United Kingdom
Start  
 
Description Tripartite Scheme
Amount $4,200,000 (USD)
Organisation InterTradeIreland 
Sector Private
Country United Kingdom
Start  
 
Description Development of a biomarker for the SRC pathway in ovarian cancer 
Organisation Almac Group
Country United Kingdom 
Sector Private 
PI Contribution The clinical samples from the SAPPROC trial have all been received and a complete pathological review of the samples has been performed by Professor Glenn McCluggage (QUB). The samples are currently under-going DNA microarray analysis using a proprietary DNA microarray platform, the Ovarian Cancer DSA™ array (Almac Diagnostics, Craigavon, UK). Correlations with signature score and response will then be made. It is anticipated that the results of this will be completed end of December 2014.
Collaborator Contribution Commercialisation of the SRC biomarker may involve require a multi-centre prospective study for EOC patients in which treatment with a SRC inhibitor is selected on the basis of the SRC assay. Almac Diagnostics has extensive experience in these types of studies and is currently delivering the biomarker in 6 clinical trials for patient treatment selection. Funding for the validation study could be applied for through the MRC DPFS/DCS scheme or Invest Northern Ireland.
Impact Ongoing
Start Year 2014
 
Description KTP Partnership with Fusion Antibodies 
Organisation Fusion Antibodies
Country United Kingdom 
Sector Private 
PI Contribution Technology developed under the project is introduced to the KTP project for validation and development in the partner company's labortatories
Collaborator Contribution The partner will employ a joint researcher with the university and devote their internal resources to the project
Impact Research is still ongoing
Start Year 2017
 
Title AN AMPHIPATHIC PEPTIDE 
Description The present invention is directed to an amphipathic peptide and methods of using the amphipathic peptide for delivering small molecule agents to a cell. Ideally, the amphipathic cell penetrating peptide comprises less than approximately 50 amino acid residues with at least 6 arginine residues, at least 12 Alanine Residues, at least 6 leucine resiues, optionally at least one cysteine residue, and at least two but no greater than three glutamic acids wherein the arginine residues are evenly distributed along the length of the peptide; and the peptide has a defined ratio of arginine to negatively charged amino acid residues and a defined ratio of hydrophilic amino acid residues to hydrophobic amino acid residues. The present invention is also directed to a nanoparticle and cell del ivery system comprising the amph ipathic cell penetrating peptide of the invention. The peptide, nanoparticle or cell delivery system of the invention may be used in therapy. For example, the peptide may be used as a therapeutic agent delivery system, in which the therapeutic agent may include nucleic acids or other small molecules. 
IP Reference WO2014087023 
Protection Patent application published
Year Protection Granted 2014
Licensed No
Impact The patent progressed to PCT and was published under WO2014087023, the patent was nationalised and is pending in the US and Europe. The technology has also been combined with WO2009040548 to achieve even greater effectiveness of delivery for vaccines.
 
Title ASSAY METHODS FOR THE DETERMINATION OF FKBPL EXPRESSION LEVEL IN THE CONTEXT OF BREAST CANCER 
Description Disclosed are methods that employ FKBPL as a marker for a subject's sensitivity to endocrine therapies in the treatment of cancers, and as a predictive marker of cancer progression and disease free survival in relation to hormone responsive cancers. 
IP Reference WO2010133880 
Protection Patent application published
Year Protection Granted 2010
Licensed No
Impact The patent is now granted in the US, published under US9110163 B2 on 18 August 2015, and China, published under CN102428370B on 25/04/2012 and is pending in Europe. This project has informed the development of the FKBPL biomarker as a companion diagnostic for ALM201 and directly contributed to the filing of a US patent continuation on 16 July 2015 which includes methods to stratify patients response to ALM201 using the biomarker.
 
Title COMPOUND 
Description Alternative methods for the detection and measurement of proteases in biological samples and compounds which allow for such detection are required to allow for rapid and selective identification of these enzymes. Compounds which allow for selective identification of these enzymes are provided with assays and kits for their use. 
IP Reference WO2011024006 
Protection Patent application published
Year Protection Granted 2011
Licensed Yes
Impact .
 
Title MODULATOR 
Description There is provided a method for suppressing a pro-inflammatory immune response in a cell, comprising providing to a cell sialic acid or analogs thereof, wherein the sialic acid or analogs are presented by a substrate such that a pro-inflammatory immune response in a cell is suppressed or an anti-inflammatory immune response is increased in a cell. Further, there is provided a method of treatment of inflammatory disease in a subject in need thereof. There is also provided a drug delivery device and a biomaterial which can modulate the inflammatory response in a subject. 
IP Reference WO2011073685 
Protection Patent granted
Year Protection Granted 2011
Licensed Yes
Impact The priority application for this patent was filed prior to the CIC project. The CIC project provided key data that led to a publication and data pack critical in securing the licence deal. Rights to the granted US patent associated with the CIC project have now been exclusively licenced to a commercial partner with options to the EP, AU, and CA granted patents. Patents were granted around 2016 / 2017 although priority date is listed above as 2011
 
Title NEATstik® (Neutrophil Elastase Airways Test) 
Description NEATstik® (Neutrophil Elastase Airways Test) has completed development and was CE marked in September 2017. NEATstik® is currently undergoing clinical validation for the real-time management of small airway inflammation in a spectrum of respiratory diseases such as CF and COPD. 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Early clinical assessment
Year Development Stage Completed 2016
Development Status Under active development/distribution
Impact Follow on funding for the Spin-out company, Pro-Axsis,has been secured from the investors as well as R&D grants from Innovate UK and Invest Northern Ireland. The first lab-based product, ProteaseTag® Active NE Immunoassay, was launched in July 2015 and sales have continued to increase since the CE mark was approved (Sept 2016) alongside uptake of the test by a number of pharma for end-point measurement in clinical trials. 
 
Company Name ProAxsis Ltd 
Description The work carried out in Dr Martin's CiC project in 2012, also attracted the early attention of AIM listed NetScientific plc, a healthcare medical technology company that commercialises research and technologies originating from leading universities. Working in partnership with NetScientific accelerated the formation of a new University spin-out venture called ProAxsis Ltd. The company has secured a range of investors including venture funding alongside Netscientific and others. 
Year Established 2014 
Impact ProAxsis was named as one of Northern Ireland's most promising technology companies, winning the annual NISP Connect 25K awards in 2013 and recently secured funding from the first round of EU Horizon 2020 funding for small businesses. By 2018, the key technology licenced into the company from the original funded project had achieved CE mark status. In addition, the company's ProteaseTag® Active NE Immunoassay, and NEATstik®, the first test to enable measurement of active neutrophil elastase at point-of-care, have been selected for inclusion in a major upcoming clinical trial. The BRIDGE study is a 3-year collaborative study, funded by the European Respiratory Society (ERS), in which 1000 patients with bronchiectasis across Europe will be recruited and will have multiple assessments including microbiome, proteomics, detailed phenotyping and imaging. The study will explore novel biomarkers and demonstrate what they can add to clinical practice.
Website https://proaxsis.com